Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancer|April 10, 2004
Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignanciesAmit Panwalkar, Srdan Verstovsek, Francis Giles
Cancer|February 11, 2004
Mammalian target of rapamycin inhibition as therapy for hematologic malignanciesAmit Panwalkar, Srdan Verstovsek, Francis J Giles
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|June 19, 2003
A model for clinical estimation of perioperative hemorrhageChristopher Howe, Christopher Paschall, Amit Panwalkar, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|June 19, 2003
Ineffectiveness of measuring routine vital signs in adult inpatients with deep venous thrombosisAnil Potti, Amit Panwalkar, Brian Hebert, et al.
American Journal of Clinical Oncology|December 15, 2004
Role of her-2/neu overexpression and clinical features at presentation as predictive factors in meningiomasAnil Potti, Amit Panwalkar, Eric Langness, et al.
Cancer Genetics and Cytogenetics|June 18, 2003
An indolent B-cell lymphoma with t(2;8)(p12;q24) abnormality and absence of C-MYC amplification and TP53 deletion. A new variant?Anil Potti, Amit Panwalkar, Mark C Ingebretson, et al.
Leukemia & Lymphoma|February 28, 2007
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myelomaJulie M Vose, Amit Panwalkar, Robert Belanger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2020
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLCMark M Awad, Shirish M Gadgeel, Hossein Borghaei, et al.
The Lancet. Oncology|October 18, 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyCorey J Langer, Shirish M Gadgeel, Hossein Borghaei, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2018
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung CancerHossein Borghaei, Corey J Langer, Shirish Gadgeel, et al.
Pageof 1